CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The IMMUTOL project focuses on developing a new immunotherapy for autoimmune diseases, particularly Multiple Sclerosis, using vitamin D3-modified dendritic cells. This approach aims to restore immune regulation and provide a long-lasting treatment option that targets the underlying causes of these diseases.
Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the cause of the disease and are required life-long.
Thus, there is an unmet need for safe and effective therapies for these diseases, which are well-tolerated and targeting the cause of disease.
Tolerogenic dendritic (DC) cell-based therapies, offer the possibility of restoring immune regulation leading to long-lasting effects.
Vitamin (Vit)D3-modified tolerogeni…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Milano
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Spain, Badalona Barcelona
Type: Research institute
Activity type: Research Organisations
SME: No
Stichting Sanquin Bloedvoorziening
Netherlands, Amsterdam
Type: Research institute
Activity type: Research Organisations
SME: No
KLINIKUM DER UNIVERSITAET REGENSBURG
Germany, Regensburg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
